Prothena Corporation PLC is a biotechnology company that specializes in the discovery, development, and commercialization of novel antibody-based therapies for the treatment of neurodegenerative diseases and rare systemic amyloidosis. With a strong pipeline of potential breakthrough treatments, Prothena is positioned to make a significant impact in the field of biopharmaceuticals.
